PubMed laboratory research record [PMID: 39948761] PubMed record related to this compound for laboratory literature review
Benefits: Helps patients achieve and maintain clinically significant weight loss Reduces appetite , hunger , and food cravings Improves blood sugar levels , blood pressure , and other cardiometabolic markers Administered once weekly with the easy-to-use FlexTouch pen Reaches full therapeutic effect at this dose, maximizing benefits for long-term weight management Side Effects: Common side effects: Nausea Vomiting Diarrhea or constipation Headache Indigestion Fatigue Abdominal discomfort Serious but less common side effects include: Pancreatitis Gallbladder problems (e.g., gallstones) Kidney issues from dehydration Increased heart rate Risk of thyroid C-cell tumors (observed in rodent studies) Warning: Do not use Wegovy if you or a family member has a history of medullary thyroid carcinoma (MTC) or MEN 2 (Multiple Endocrine Neoplasia syndrome type 2)
By targeting the NNMT pathway, it helps restore metabolic balance , enhance energy , and potentially support sustainable fat loss without stimulants or hormonal interference
doi:10.1093/ajcn/77.1.189 4
of 0.624 reflecting a minimized cross-reaction
Over the past two decades, it has consistently demonstrated multimodal geroprotective effects across cellular, animal, and early human studies
